Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.

ABSTRACT:

Introduction

The real-life effectiveness of adalimumab biosimilars in patients with psoriasis has rarely been investigated.

Objective

To investigate drug survival of adalimumab biosimilars in patients with chronic plaque psoriasis and factors associated with its discontinuation.

Methods

We carried out a retrospective observational study including all consecutive patients with chronic plaque psoriasis who initiated adalimumab biosimilar MSB11022 (Idacio), ABP501 (Amgevita), or SB5 (Imraldi) between 1 January 2018 and 1 January 2021. The 1-year drug survival of adalimumab biosimilar and independent factors associated with its discontinuation were investigated. Cox regression models were fit to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) fo

SUBMITTER: Bellinato F 

PROVIDER: S-EPMC9209594 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature